P01-011 – Colchicine compliance and amyloidosis by unknown
MEETING ABSTRACT Open Access
P01-011 – Colchicine compliance and amyloidosis
H Ozdogan*, S Ugurlu, G Hatemi
From 7th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID)
Lausanne, Switerland. 22-26 May 2013
Objectives
To assess colchicine compliance in patients with familial
Mediterranean fever and amyloidosis prior to the devel-
opment of amyloidosis.
Methods
Twenty-six patients with FMF amyloidosis were ques-
tionned for disease onset, date of diagnosis for FMF and
amyloidosis, delay in diagnosis, colchicine dose, response,
compliance, disease manifestations, family history, and
associated diseases.
Results
In 14 of the 26 patients, FMF and amyloidosis were
diagnosed at the same time with a mean delay in diagnosis
of 22 ±9.2 years. In the remaining 12, there was a mean
delay of 9.6±8 years from the onset to the diagnosis of
FMF and 23±9.6 years from the onset to the diagnosis of
amyloidosis. These patients were on colchicine for a mean
of 13±7.6 years after the diagnosis of FMF. Eight were
non-compliant, however 4 were compliant and recieved
1.5 mg/day of colchicine for a mean of 7.5 years (range
4-12 years) before the development of amyloidosis. One of
these 4 compliant patients stopped colchicine 1 year prior
to the diagnosis of amyloidosis after 12 years of treatment.
Response to Colchicine was reported in 3 patients. History
of amyloidosis was present in one and history of FMF in
3 of the 4 compliant patients. None had an associated
disease. Two were homozygous and one was heterozygous
for M694V.
Conclusion
This retrospective data may indicate that in a proportion
of patients with FMF who had recieved a proper dose of
Colchicine can still develop amyloidosis. This observation
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